Filtered By:
Condition: Polyps

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 2492 results found since Jan 2013.

Crocin Inhibits the Type 2 Inflammatory Response Produced by ILC2s in Eosinophilic Nasal Polyps
CONCLUSION: Crocin inhibited type 2 inflammation induced by ILC2 activation at low concentrations via inhibiting the activation of NF-κB.PMID:37424236 | DOI:10.1177/19458924231185296
Source: American Journal of Rhinology and Allergy - July 10, 2023 Category: ENT & OMF Authors: Xu Xiaodong Li Tao Liu Jianmin Zhou Jing Zhong Bing Du Jintao Claus Bachert Ba Luo Source Type: research

Type 17 mucosal-associated invariant T cells contribute to neutrophilic inflammation in patients with nasal polyps
The roles of MAIT cells and their subsets on airway neutrophilic inflammation remain unclear. Type 17 MAIT subsets could be novel cellular targets for the therapeutic strategy of neutrophilic inflammation in nasal mucosa.
Source: Journal of Allergy and Clinical Immunology - July 10, 2023 Category: Allergy & Immunology Authors: Xiaoyan Ye, Yachun Li, Bixing Fang, Yizhang Yuan, Danni Feng, Hexin Chen, Jian Li, Qingxiang Meng, Shaobing Xiong, Dongmei Ye, Linyi Jiao, Dehua Chen, Ruchong Chen, Wenbin Lei, Yifang Gao, Chun Wei Li Source Type: research

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) treated with omalizumab, dupilumab or mepolizumab: review of the current knowledge towards an attempt to compare agents ’ efficacy – A systematic review
ConclusionsAlthough the present analysis showed a moderate supremacy of dupilumab, there is still no evidence-based answer to the question “which biologic agent is the most effective in CRS treatment?” Improved statistical methodology, head-to-head trials and real-life studies could lead to more robust conclusions, establishing the real role of the specific biologic agents.This article is protected by copyright. All rights reserved
Source: International Forum of Allergy and Rhinology - July 3, 2023 Category: Allergy & Immunology Authors: Georgios X. Papacharalampous, Jannis Constantinidis, George Fotiadis, Nan Zhang, Claus Bachert, Michael Katotomichelakis Tags: REVIEW ARTICLE Source Type: research

Real ‐world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis (CRS) in the US: Impact of comorbidity and sinus surgery
ConclusionsConsistent with trial data, mepolizumab use in real-world practice shows benefits across comorbid patient cohorts with more pronounced impact in those with severe asthma+comorbid CRS+sinus surgery.This article is protected by copyright. All rights reserved
Source: International Forum of Allergy and Rhinology - June 27, 2023 Category: Allergy & Immunology Authors: Jared Silver, Arijita Deb, Fran çois Laliberté, Chi Gao, Neil Bhattacharyya Tags: ORIGINAL ARTICLE Source Type: research

Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24 ‐week treatment‐free follow‐up
Conclusion52 weeks of mepolizumab treatment is associated with sustained clinical benefits up to 24 weeks after discontinuation in patients with severe CRSwNP, which should be considered by physicians when making treatment decisions.This article is protected by copyright. All rights reserved
Source: International Forum of Allergy and Rhinology - June 23, 2023 Category: Allergy & Immunology Authors: Martin Desrosiers, Zuzana Diamant, Paolo Castelnuovo, Peter W Hellings, Joseph K Han, Anju T Peters, Jared Silver, Steven G Smith, Abigail Fuller, Ana R Sousa, Robert H Chan, Philippe Gevaert Tags: ORIGINAL ARTICLE Source Type: research

Risk Factors for Recurrence of Nasal Polyps after Endoscopic Sinus Surgery in Patients with Allergic Chronic Rhino Sinusitis
AbstractRhino sinusitis, is a common inflammatory disease that affects the nasal cavity and paranasal sinuses in millions of individuals. Chronic sinusitis patients complain of a combination of nasal obstruction, rhinorrhea, post nasal drip and facial pain. To identify the risk factors of the recurrence of nasal polyps in chronic rhino sinusitis patients after endoscopic sinus surgery. After a review of 60 patients with chronic rhino sinusitis with failed medical treatment requiring FESS presenting in Kasr Alainy Hospital in Cairo University and October 6 University Hospital from May 2022 to March 2023. All patients were s...
Source: Indian Journal of Otolaryngology and Head and Neck Surgery - June 23, 2023 Category: ENT & OMF Source Type: research

Perioperative mepolizumab in aspirin-exacerbated respiratory disease does not prevent nasal polyp regrowth
Ann Allergy Asthma Immunol. 2023 Jun 17:S1081-1206(23)00442-8. doi: 10.1016/j.anai.2023.06.017. Online ahead of print.NO ABSTRACTPMID:37336258 | DOI:10.1016/j.anai.2023.06.017
Source: Annals of Allergy, Asthma and Immunology - June 19, 2023 Category: Allergy & Immunology Authors: Andrew D Supron Regan W Bergmark Rachel E Roditi Kathleen M Buchheit Source Type: research

Eosinophils and tissue remodeling: relevance to airway disease
The ability of human tissue to reorganize and restore its existing structure underlies tissue homeostasis in the healthy airways, but in disease can persist without normal resolution, leading to an altered airway structure. Eosinophils play a cardinal role in airway remodeling both in health and disease, driving epithelial homeostasis and extracellular matrix turnover. Physiological consequences associated with eosinophil-driven remodeling include impaired lung function and reduced bronchodilator reversibility in asthma, and obstructed airflow in chronic rhinosinusitis with nasal polyps (CRSwNP).
Source: Journal of Allergy and Clinical Immunology - June 18, 2023 Category: Allergy & Immunology Authors: Salman Siddiqui, Claus Bachert, Leif Bjermer, Kathleen M. Buchheit, Mario Castro, Yimin Qin, Hitasha Rupani, Hironori Sagara, Peter Howarth, Camille Taill é Source Type: research

Perioperative mepolizumab in aspirin-exacerbated respiratory disease does not prevent nasal polyp regrowth
Aspirin-exacerbated respiratory disease (AERD) is defined by the triad of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and respiratory reactions to medications that inhibit cyclooxygenase-1. Of these elements, patients with AERD cite CRSwNP symptoms as the most impactful on quality of life1. Patients with AERD are less likely to respond to first-line therapy with intranasal glucocorticoids and more likely to require multiple functional endoscopic sinus surgeries (FESS) compared to aspirin-tolerant CRSwNP2.
Source: Annals of Allergy, Asthma and Immunology - June 17, 2023 Category: Allergy & Immunology Authors: Andrew D. Supron, Regan W. Bergmark, Rachel E. Roditi, Kathleen M. Buchheit Source Type: research

Predictive factors of revision endoscopic sinus surgery
ConclusionsFactors like peripheral eosinophilia and Lund –Mackay score were associated with a higher probability of revision ESS. Applying these concepts to the clinical practice could help predict the evolution of patient’s pathology in the post-operative period and identify in advance those cases that may need a multidisciplinary approach.
Source: European Archives of Oto-Rhino-Laryngology - June 15, 2023 Category: ENT & OMF Source Type: research

Mir ‐200a‐3p regulates epithelial‐mesenchymal transition and inflammation in chronic rhinosinusitis with nasal polyps by targeting zeb1 via erk/p38 pathway
ConclusionsMiR-200a-3p suppresses EMT and inflammation by regulating the expression of ZEB1 via the ERK/P38 pathway. Our study provides new ideas for protecting nasal epithelial cells from tissue remodeling and finding a possible target for disease.This article is protected by copyright. All rights reserved
Source: International Forum of Allergy and Rhinology - June 15, 2023 Category: Allergy & Immunology Authors: Yisha Wu, Kaiyue Sun, Yanyi Tu, Ping Li, Dingqian Hao, Peng Yu, Aiping Chen, Yuzhu Wan, Li Shi Tags: ORIGINAL ARTICLE Source Type: research